Novamind's clinic revenues jumped 43% quarter-over-quarter, to CAD$1.85 million. Projecting a 225% increase in clinic visits year-over-year.
Novamind's clinic revenues jumped 43% quarter-over-quarter, to CAD$1.85 million. Projecting a 225% increase in clinic visits year-over-year.
Mydecine receives regulatory approval to expand its psilocybin mushroom cultivation operations.
MindMed executes an MOU to access the drug delivery system of Israel-based Nextage Therapeutics.
NASDAQ-listed Enveric Biosciences is merging with private psychedelics company, Magic Med Industries.
Wesana's new Chief Scientific Officer has deep experience in the pharmaceutical industry with Pfizer and GSK.
MINDCURE announces the addition of Dr. Joel Raskin as its new Chief Medical Officer. Experience includes leadership positions with drug developer, Eli Lilly & Co.
Mindmed's drug R&D is broadening to include mescaline, after approval by a Swiss ethics committee of a new mescaline-based study.
Field Trip appoints a former high-ranking Democrat as a Special Advisor to the company.
Cybin's 12th patent application further supports the company's novel molecule development.
Mydecine reports a net loss of CAD$5.2 million for Q1 2021, with cash and cash equivalents of CAD$11.3 million at the end of the quarter.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now